Table 2.

Past clinical trials targeting the microenvironment of PDA.

Target	Agent	Combination	Identifier	Status	Results
BTK	ACP-196	Pembrolizumab	NCT02362048	Completed	Well tolerated, limited clinical activity
	Ibrutinib	Durvalumab	NCT02403271	Completed	Well tolerated
		Gemcitabine and Nab-Paclitaxel	NCT02562898	Active, not recruiting	Ineffective
CD40	CP-870,893	chemotherapy	NCT00711191	Completed	Partially effective
	RO7009789	Gemcitabine and Nab-Paclitaxel	NCT02588443	Completed	Acceptable toxicity and clinical activity
	APX005M	Gemcitabine and Nab-Paclitaxel with or without Nivolumab	NCT03214250	Active, not recruiting	Manageable toxicity and early efficacy
CSF1R	Pexidartinib	Durvalumab	NCT02777710	Completed	Acceptable toxicity
	Cabiralizumab	Nivolumab	NCT02526017	Completed	Partially effective
		Nivolumab	NCT03336216	Active, not recruiting	Ineffective
DC	DC vaccine		NCT03114631	Completed	Safe with early clinical efficacy
RIPK1	GSK3145095		NCT03681951	Terminated	Serious adverse events
TGFβR1	Galunisertib	Durvalumab	NCT02734160	Completed	Partially effective

Clinical trial identifier from https://clinicaltrials.gov. BTK, Bruton tyrosine kinase; CSF1R, colony-stimulating factor 1 receptor; DC, dendritic cell; Receptor-interacting serine/threonine protein kinase 1 (RIPK1); TGFβR, transforming growth factor β receptor.